Special Article
Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19
Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
Read
4033
Timeswas read the article
1327
Total PDF
2706
Total HTML
Share statistics
array:24 [ "pii" => "S2173574321000952" "issn" => "21735743" "doi" => "10.1016/j.reumae.2020.04.012" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1420" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2021;17:309-12" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X20300863" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2020.04.009" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1420" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2021;17:309-12" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artículo especial</span>" "titulo" => "Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "309" "paginaFinal" => "312" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 4368 "Ancho" => 2917 "Tamanyo" => 884479 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Fisiopatología del SDRA. El estímulo inflamatorio inicial activa a macrófagos alveolares a través de señalización TLR y NLRP. Los macrófagos alveolares activados liberan citosinas proinflamatorias y reclutan macrófagos circulantes y neutrófilos a los sitios lesionados. Esta afluencia de neutrófilos y macrófagos activados persistentemente causan daños extensos en epitelios y endotelios pulmonares, lo que da como resultado un deterioro barrera alveolar-capilar.</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">ENaC: canal de sodio epitelial; Na: sodio; NET: trampas extracelulares de neutrófilos; TLR: receptor tipo toll; U: ubiquinización.</p> <p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Fuente: versión adaptada del original de Seung Hye Han. et al. Ilustrador científico: Miguel Soto.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alejandro Muñoz-Jiménez, Esteban Rubio-Romero, José Luis Marenco de la Fuente" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Muñoz-Jiménez" ] 1 => array:2 [ "nombre" => "Esteban" "apellidos" => "Rubio-Romero" ] 2 => array:2 [ "nombre" => "José Luis" "apellidos" => "Marenco de la Fuente" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574321000952" "doi" => "10.1016/j.reumae.2020.04.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321000952?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X20300863?idApp=UINPBA00004M" "url" => "/1699258X/0000001700000006/v1_202105200700/S1699258X20300863/v1_202105200700/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574321001143" "issn" => "21735743" "doi" => "10.1016/j.reumae.2019.10.008" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1377" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2021;17:313-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Validity of the Cushing’s syndrome severity index in patients with iatrogenic Cushing’s syndrome" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "313" "paginaFinal" => "317" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Validación del índice de gravedad del síndrome de Cushing en pacientes con síndrome de Cushing iatrógénico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1318 "Ancho" => 1667 "Tamanyo" => 64682 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Adverse effects from glucocorticoid usage reported by the physician.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Everardo Álvarez-Hernández, Graciela Mercado-Molina, Rosa Consuelo Barrera-Guerra" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Everardo" "apellidos" => "Álvarez-Hernández" ] 1 => array:2 [ "nombre" => "Graciela" "apellidos" => "Mercado-Molina" ] 2 => array:2 [ "nombre" => "Rosa Consuelo" "apellidos" => "Barrera-Guerra" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X19301652" "doi" => "10.1016/j.reuma.2019.10.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X19301652?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321001143?idApp=UINPBA00004M" "url" => "/21735743/0000001700000006/v1_202105240506/S2173574321001143/v1_202105240506/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2173574321001155" "issn" => "21735743" "doi" => "10.1016/j.reumae.2021.03.003" "estado" => "S300" "fechaPublicacion" => "2021-06-01" "aid" => "1528" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2021;17:307-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Treatment of psoriatic arthritis: Challenges in Latin America" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "307" "paginaFinal" => "308" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento de la artritis psoriásica: retos y desafíos en Latino América" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Wilson Bautista Molano" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Wilson Bautista" "apellidos" => "Molano" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X21000954" "doi" => "10.1016/j.reuma.2021.03.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X21000954?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321001155?idApp=UINPBA00004M" "url" => "/21735743/0000001700000006/v1_202105240506/S2173574321001155/v1_202105240506/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>" "titulo" => "Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "309" "paginaFinal" => "312" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Alejandro Muñoz-Jiménez, Esteban Rubio-Romero, José Luis Marenco de la Fuente" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Alejandro" "apellidos" => "Muñoz-Jiménez" "email" => array:1 [ 0 => "amj@ser.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Esteban" "apellidos" => "Rubio-Romero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "José Luis Marenco de la" "apellidos" => "Fuente" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Virgen de Valme, Sevilla, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 4368 "Ancho" => 2917 "Tamanyo" => 856614 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Pathophysiology of ARDS. The initial inflammatory stimulus activates alveolar macrophages through TLR and NLRP signalling. Activated alveolar macrophages release proinflammatory cytokines and recruit circulating macrophages and neutrophils to injury sites. This influx of persistently activated neutrophils and macrophages causes extensive damage to epithelial and endothelial lung tissue, resulting in an impaired alveolar-capillary barrier.</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">ENaC: Epithelial sodium channel; Na: Sodium; NETs: Neutrophil Extracellular Traps; TLR: Toll-like receptor; U: Ubiquitination.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Source: version adapted from the original by Seung Hye Han et al. Scientific illustrator: Miguel Soto.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">One of the most serious complications in patients infected with COVID-19 is cardiopulmonary failure termed acute respiratory distress syndrome (ARDS).<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Since 1995, several authors have highlighted the central role of IL-1 Beta (IL-1) in the inflammatory cascade of ARDS.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> There are 2 publications involving more than 20 patients, showing elevated IL-1β levels in plasma and bronchoalveolar lavage. In addition to these publications, many others describe an increase in countless proinflammatory cytokines (IL-1, IL-6, TNF-alpha, IL-8, etc.) in the alveoli of patients with ARDS.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">In 2018, Aranda-Valderrama and Kaynar published a model to determine the flow of cytokines and proinflammatory cells in the pulmonary alveoli of patients affected by ARDS.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> They observed how inactive IL-1β (pro-IL-1β) progresses to active IL-1β inside the alveolar macrophages (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). This IL-1β generates the activation of the alveolar macrophage, thereby triggering the release of proinflammatory molecules such as IL-6, IL-18, TNF, G-CSF and CCCL2.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">In 2006, He et al. studied the high number of inflammatory cytokines in patients with ARDS secondary to coronavirus (CoV) infection. Autopsies of these patients showed elevated MCP-1, TGF-β1, TNF-α, IL-1β and IL-6.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">This and other publications<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> also study the NLPR3 inflammasome and its influence on alveolar macrophage activation in ARDS patients. This is a complex of proteins that interact in a unidirectional manner generating an inflammatory cascade. Innate immunity responds to infection and tissue damage by activating this molecular platform. In human clinical research, four classes of inflammasomes related to inflammatory processes have been described: NLRP1, NLRC4, NLRP3 and AIM-2.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Of these, NLRP3 is the best studied. Inflammasomes have the common purpose of processing and activating caspase-1, the enzyme responsible for the maturation of pro-IL-1β y and pro-IL-18.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">This protein group can detect molecular patterns linked to potential danger, either endogenous (DAMPs) or exogenous (PAMPs) signals that activate various intracellular signalling pathways, mainly through toll-like receptors (TLRs), culminating in the activation of different pro-inflammatory transcription factors such as nuclear factor kappa B (NF-kB) or activator protein 1 (AP-1). These danger signals can also lead to inflammasome activation and maturation of de IL-1β and IL-18 (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). The NLRP3 inflammasome can cause epithelial and endothelial damage in the lung parenchyma, leading to severe respiratory disorders such as ARDS and acute lung injury (ALI), possibly resulting in severe pneumonia.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">It is likely that COVID-19 infection can trigger a violent immune response and in turn activate the NLRP3 inflammasome in alveolar macrophages, causing a potentially fatal “storm” of cytokines, notably IL-1β.</p><p id="par0040" class="elsevierStylePara elsevierViewall">We currently have a drug called anakinra, which neutralises the biological activity of interleukin-1 alpha and ß by competitively inhibiting their binding to the interleukin-1 type I receptor. Another available molecule is canakinumab, which binds with high affinity specifically to IL-1β and neutralises its biological activity by blocking interaction with IL-1 receptors, thus preventing IL-1β induced gene activation and the production of inflammatory mediators.</p><p id="par0045" class="elsevierStylePara elsevierViewall">These drugs that can block IL-1β activity have shown efficacy in the treatment of autoinflammatory diseases such as neonatal-onset multisystem inflammatory disease (CINCA), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), Still's disease and cryopyrin-associated diseases, a rare genetic disease caused by an autosomal dominant mutation in the NLRP3 gene.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">The link between the presence of an NLRP3 inflammasome and the origin of the inflammatory cascade in ARDS has been confirmed in the medical literature.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11,12</span></a> The initiating pathway of IL-1β makes it a specific and central target for controlling the pro-inflammatory picture generated in the pulmonary alveolus. It is thus a potential therapeutic target in patients who may progress to ARDS after COVID-19 infection. The use of anakinra (anti IL 1β R) or canakinumab (anti IL 1β) is a therapeutic option to control alveolar inflammation secondary to COVID-19 infection.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">However, these are different drugs with equally different pharmacokinetics and pharmacodynamics. The peak serum concentration (C<span class="elsevierStyleInf">max</span>) of canakinumab occurs approximately 7 days after a single subcutaneous dose of 150 mg administered to patients with cryopyrin-associated periodic syndrome (adult CAPS). The mean terminal half-life is 26 days and mean peak plasma concentration (C<span class="elsevierStyleInf">max</span>) after a single subcutaneous dose of 150 mg in a typical adult CAPS patient (70 kg) is 15.9 μg/mL and an absolute bioavailability after subcutaneous administration of 66%.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Anakinra, in contrast, has an absolute bioavailability of 95% for healthy adults after a 70 mg subcutaneous bolus injection. The C<span class="elsevierStyleInf">max</span> of anakinra is generally 3–7 h after subcutaneous administration of clinically relevant doses (1−2 mg/kg/day) and the terminal half-life ranges from 4 h to 6 h. It is therefore a drug with a shorter half-life than canakinumab and thus with great potential for use in a clinical emergency such as ARDS due to COVID-19.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">It is likely that using the immunosuppressive biologic therapies is a way to control ARDS due to COVID-19. However, other scenarios must be considered beyond the individual potential of each molecule where even 2 or more of these lines of treatment can be added. While we need randomised clinical trials to advance the safety and efficacy of anakinra in ARDS due to COVID-19, this option should be considered when current treatments are ineffective or unavailable.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conflict of interests</span><p id="par0065" class="elsevierStylePara elsevierViewall">The authors have no conflict of interests to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:6 [ 0 => array:3 [ "identificador" => "xres1515118" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1373922" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1515117" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1373923" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflict of interests" ] 5 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2020-03-25" "fechaAceptado" => "2020-04-10" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1373922" "palabras" => array:5 [ 0 => "Anakinra" 1 => "Covid-19" 2 => "Acute respiratory distress syndrome" 3 => "Inflamosome" 4 => "IL-1β" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1373923" "palabras" => array:5 [ 0 => "Anakinra" 1 => "Covid-19" 2 => "Síndrome de distres respiratorio agudo" 3 => "Inflamasoma" 4 => "IL-1β" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">El desenlace de la infección por SARS-CoV-2 (COVID-19) afecta fundamentalmente al campo pulmonar, ocasionando un cuadro de SÍNDROME DE DISTRÉS RESPIRATORIO AGUDO (SDRA). Este proceso es un cuadro inflamatorio, protagonizado por una cascada de citocinas bajo el amparo del INFLAMOSOMA NLRP3, responsable principal de la destrucción alveolar. De entre todas las citocinas que se desencadenan en este cuadro destaca la IL beta. ANAKINRA es un potente fármaco biológico, capaz de bloquear esta IL 1 beta. Proponemos su uso, de cara a controlar el SDRA secundario a la infección por COVID-19.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Muñoz-Jiménez A, Rubio-Romero E, Fuente JLM. Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19. Reumatol Clin. 2021;17:309–312.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4209 "Ancho" => 2932 "Tamanyo" => 1628497 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Pathogenesis of acute respiratory distress syndrome (ARDS) is triggered after an initial injury that interacts through alarmin receptors and TLRs that activate nuclear transcription factors, including NF-κB. Subsequently, a potent acute immune response triggered primarily by IL-1ß results in macrophage/neutrophil activation and recruitment. The cell-mediated immune response results in tissue damage, which promotes the development of oedema and epithelial damage.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">IL: interleukin; MAPK: Mitogen-activated protein kinase; MMPs: Matrix metalloproteinases; NETs: Neutrophil extracellular traps; PAMPS: Pathogen-associated molecular patterns; ROS: Reactive oxygen species; TLR: Toll-like receptor.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Source: version adapted from the original by Aranda-Valderrama et al. Scientific illustrator: Miguel Soto.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 4368 "Ancho" => 2917 "Tamanyo" => 856614 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Pathophysiology of ARDS. The initial inflammatory stimulus activates alveolar macrophages through TLR and NLRP signalling. Activated alveolar macrophages release proinflammatory cytokines and recruit circulating macrophages and neutrophils to injury sites. This influx of persistently activated neutrophils and macrophages causes extensive damage to epithelial and endothelial lung tissue, resulting in an impaired alveolar-capillary barrier.</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">ENaC: Epithelial sodium channel; Na: Sodium; NETs: Neutrophil Extracellular Traps; TLR: Toll-like receptor; U: Ubiquitination.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Source: version adapted from the original by Seung Hye Han et al. Scientific illustrator: Miguel Soto.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of hospitalized patients with acute respiratory distress syndrome caused by COVID-19 and H1N1" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "X. Tang" 1 => "R. Du" 2 => "R. Wang" 3 => "T. Cao" 4 => "L. Guan" 5 => "C. Yang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.chest.2020.03.032" "Revista" => array:3 [ "tituloSerie" => "Chest." "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11115464" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.U. Meduri" 1 => "S. Headley" 2 => "G. Kohler" 3 => "F. Stentz" 4 => "E. Tolley" 5 => "R. Umberger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.107.4.1062" "Revista" => array:6 [ "tituloSerie" => "Chest." "fecha" => "1995" "volumen" => "107" "paginaInicial" => "1062" "paginaFinal" => "1073" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7705118" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G.U. Meduri" 1 => "G. Kohler" 2 => "S. Headley" 3 => "E. Tolley" 4 => "F. Stentz" 5 => "A. Postlethwaite" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.108.5.1303" "Revista" => array:6 [ "tituloSerie" => "Chest." "fecha" => "1995" "volumen" => "108" "paginaInicial" => "1303" "paginaFinal" => "1314" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7587434" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.A. Dinarello" 1 => "A. Simon" 2 => "J.W. van der Meer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrd3800" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Drug Discov." "fecha" => "2012" "volumen" => "11" "paginaInicial" => "633" "paginaFinal" => "652" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22850787" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The basic science and molecular mechanisms of lung injury and acute respiratory distress syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P. Aranda-Valderrama" 1 => "A.M. Kaynar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/AIA.0000000000000207" "Revista" => array:6 [ "tituloSerie" => "Int Anesthesiol Clin." "fecha" => "2018" "volumen" => "56" "paginaInicial" => "1" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30204601" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. He" 1 => "Y. Ding" 2 => "Q. Zhang" 3 => "X. Che" 4 => "Y. He" 5 => "H. Shen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/path.2067" "Revista" => array:6 [ "tituloSerie" => "J Pathol." "fecha" => "2006" "volumen" => "210" "paginaInicial" => "288" "paginaFinal" => "297" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17031779" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The acute respiratory distress syndrome: from mechanism to translation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Han" 1 => "R.K. Mallampalli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4049/jimmunol.1402513" "Revista" => array:6 [ "tituloSerie" => "J Immunol." "fecha" => "2015" "volumen" => "194" "paginaInicial" => "855" "paginaFinal" => "860" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25596299" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sensing and reacting to microbes through the inflammasomes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Franchi" 1 => "R. Munoz-Planillo" 2 => "G. Núñez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ni.2231" "Revista" => array:6 [ "tituloSerie" => "Nat Immunol." "fecha" => "2012" "volumen" => "13" "paginaInicial" => "325" "paginaFinal" => "332" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22430785" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Critical role for the NLRP3 inflammasome during acute lung injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.J. Grailer" 1 => "B.A. Canning" 2 => "M. Kalbitz" 3 => "M.D. Haggadone" 4 => "R.M. Dhond" 5 => "A.V. Andjelkovic" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4049/jimmunol.1400368" "Revista" => array:6 [ "tituloSerie" => "J Immunol." "fecha" => "2014" "volumen" => "192" "paginaInicial" => "5974" "paginaFinal" => "5983" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24795455" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.D. Jones" 1 => "T.R. Crother" 2 => "R.A. Gonzalez-Villalobos" 3 => "M. Jupelli" 4 => "S. Chen" 5 => "J. Dagvadorj" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1165/rcmb.2013-0087OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Cell Mol Biol." "fecha" => "2014" "volumen" => "50" "paginaInicial" => "270" "paginaFinal" => "280" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24007300" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Melatonin as an anti-inflammatory agent modulating inflammasome activation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. Favero" 1 => "L. Franceschetti" 2 => "F. Bonomini" 3 => "L.F. Rodella" 4 => "R. Rezzani" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Int J Endocrinol." "fecha" => "2017" "volumen" => "2017" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.A. Dinarello" 1 => "A. Simon" 2 => "J.W. van der Meer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrd3800" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Drug Discov." "fecha" => "2012" "volumen" => "11" "paginaInicial" => "633" "paginaFinal" => "652" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22850787" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.B. Willingham" 1 => "I.C. Allen" 2 => "D.T. Bergstralh" 3 => "W.J. Brickey" 4 => "M.T. Huang" 5 => "D.J. Taxman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4049/jimmunol.0900138" "Revista" => array:6 [ "tituloSerie" => "J Immunol." "fecha" => "2009" "volumen" => "183" "paginaInicial" => "2008" "paginaFinal" => "2015" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19587006" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "R.M. Fleischmann" 1 => "J. Schechtman" 2 => "R. Bennett" 3 => "M.L. Handel" 4 => "G.R. Burmester" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.10870" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum." "fecha" => "2003" "volumen" => "48" "paginaInicial" => "927" "paginaFinal" => "934" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12687534" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Kacar" 1 => "S. Savic" 2 => "J.C.H. van der Hilst" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/JIR.S206204" "Revista" => array:6 [ "tituloSerie" => "J Inflamm Res." "fecha" => "2020" "volumen" => "13" "paginaInicial" => "141" "paginaFinal" => "149" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32210604" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001700000006/v1_202105240506/S2173574321000952/v1_202105240506/en/main.assets" "Apartado" => array:4 [ "identificador" => "5793" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001700000006/v1_202105240506/S2173574321000952/v1_202105240506/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321000952?idApp=UINPBA00004M" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 2 | 8 |
| 2024 October | 62 | 30 | 92 |
| 2024 September | 72 | 20 | 92 |
| 2024 August | 94 | 49 | 143 |
| 2024 July | 77 | 29 | 106 |
| 2024 June | 81 | 50 | 131 |
| 2024 May | 80 | 33 | 113 |
| 2024 April | 83 | 47 | 130 |
| 2024 March | 84 | 65 | 149 |
| 2024 February | 105 | 50 | 155 |
| 2024 January | 60 | 43 | 103 |
| 2023 December | 55 | 37 | 92 |
| 2023 November | 69 | 39 | 108 |
| 2023 October | 72 | 30 | 102 |
| 2023 September | 146 | 40 | 186 |
| 2023 August | 70 | 24 | 94 |
| 2023 July | 88 | 32 | 120 |
| 2023 June | 69 | 32 | 101 |
| 2023 May | 87 | 24 | 111 |
| 2023 April | 73 | 18 | 91 |
| 2023 March | 82 | 35 | 117 |
| 2023 February | 71 | 34 | 105 |
| 2023 January | 54 | 24 | 78 |
| 2022 December | 102 | 46 | 148 |
| 2022 November | 81 | 48 | 129 |
| 2022 October | 91 | 32 | 123 |
| 2022 September | 88 | 39 | 127 |
| 2022 August | 104 | 33 | 137 |
| 2022 July | 111 | 39 | 150 |
| 2022 June | 52 | 36 | 88 |
| 2022 May | 61 | 44 | 105 |
| 2022 April | 60 | 39 | 99 |
| 2022 March | 49 | 59 | 108 |
| 2022 February | 51 | 40 | 91 |
| 2022 January | 67 | 37 | 104 |
| 2021 December | 42 | 45 | 87 |
| 2021 November | 7 | 3 | 10 |
Show all
